Humblet-Baron, S., Schönefeldt, S., Garcia-Perez, J. E., Baron, F., Pasciuto, E., & Liston, A. (November 2017). Cytotoxic T-lymphocyte-associated protein 4-Ig effectively controls immune activation and inflammatory disease in a novel murine model of leaky severe combined immunodeficiency. Journal of Allergy and Clinical Immunology, 140 (5), 1394-1403.e8. doi:10.1016/j.jaci.2016.12.968 Peer Reviewed verified by ORBi |
Ehx, G., Somja, J., Fransolet, G., Delens, L., Muller, J., Beguin, Y., Humblet-Baron, S., & Baron, F. (14 October 2016). Comparison of xenogeneic graft-versus-host reactions in humanized NSG and NSG-HLA-A2/HHD mice [Poster presentation]. Regulatory T cells mini-symposium, Leuven, Belgium. |
Tian, L., De Hertogh, G., Fedeli, M., Staats, K. A., Schonefeldt, S., Humblet, S., Van Den Bosch, L., Dellabona, P., Dooley, J., & Liston, A. (2012). Loss of T cell microRNA provides systemic protection against autoimmune pathology in mice. Journal of Autoimmunity. doi:10.1016/j.jaut.2011.12.004 Peer Reviewed verified by ORBi |
Humblet, S., Baron, F., & Liston, A. (2011). Regulatory T cells fulfil their promise ? Immunology and Cell Biology, 89, 825-826. doi:10.1038/icb.2011.52 Peer Reviewed verified by ORBi |
Sather, B. D., Ryu, B. Y., Stirling, B. V., Garibov, M., Kerns, H. M., Humblet, S., Astrakhan, A., & Rawlings, D. J. (2011). Development of B-lineage predominant lentiviral vectors for use in genetic therapies for B cell disorders. Molecular Therapy, 19 (3), 515-25. doi:10.1038/mt.2010.259 Peer Reviewed verified by ORBi |
CASTERMANS, E., Hannon, M., Dutrieux, J., Humblet, S., Seidel, L., Cheynier, R., Willems, E., Gothot, A., Vanbellinghen, J.-F., Geenen, V., Sandmaier, B. M., Storb, R., Beguin, Y., & Baron, F. (2011). Thymic recovery after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning is limited to patients younger than 60 years of age. Haematologica, 96(2), 298-306. doi:10.3324/haematol.2010.029702 Peer Reviewed verified by ORBi |
Kerns, H. M., Ryu, B. Y., Stirling, B. V., Sather, B. D., Astrakhan, A., Humblet, S., Liggitt, D., & Rawlings, D. J. (2010). B cell-specific lentiviral gene therapy leads to sustained B-cell functional recovery in a murine model of X-linked agammaglobulinemia. Blood, 115 (11), 2146-55. doi:10.1182/blood-2009-09-241869 Peer Reviewed verified by ORBi |
Willems, E., Humblet-Baron, S., Dengis, O., Seidel, L., Beguin, Y., & Baron, F. (2010). Elevations of tumor necrosis factor-receptor-1 at day 7 and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Bone Marrow Transplantation, 45, 1442-1448. doi:10.1038/bmt.2009.360 Peer Reviewed verified by ORBi |
Humblet-Baron, S. (2009). Regulatory T cells in Wiskott-Aldrich syndrome and after allogeneic transplantation with nonmyeloablative conditioning [Doctoral thesis, ULiège - Université de Liège]. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/110441 |
Meyer-Bahlburg, A., Becker-Herman, S., Humblet, S., Khim, S., Weber, M., Bouma, G., Thrasher, A. J., Batista, F. D., & Rawlings, D. J. (2008). Wiskott-Aldrich syndrome protein deficiency in B cells results in impaired peripheral homeostasis. Blood, 112 (10), 4158-69. doi:10.1182/blood-2008-02-140814 Peer Reviewed verified by ORBi |
Humblet, S., Sather, B., Anover, S., Becker-Herman, S., Kasprowicz, D. J., Khim, S., Nguyen, T., Hudkins-Loya, K., Alpers, C. E., Ziegler, S. F., Ochs, H., Torgerson, T., Campbell, D. J., & Rawlings, D. J. (2007). Wiskott-Aldrich syndrome protein is required for regulatory T cell homeostasis. Journal of Clinical Investigation, 117 (2), 407-18. doi:10.1172/JCI29539 Peer Reviewed verified by ORBi |
Yu, P. W., Tabuchi, R. S., Kato, R. M., Astrakhan, A., Humblet, S., Kipp, K., Chae, K., Ellmeier, W., Witte, O. N., & Rawlings, D. J. (2004). Sustained correction of B-cell development and function in a murine model of X-linked agammaglobulinemia (XLA) using retroviral-mediated gene transfer. Blood, 104 (5), 1281-90. doi:10.1182/blood-2003-09-3044 Peer Reviewed verified by ORBi |
Baron, F., Schaaf-Lafontaine, N., Humblet-Baron, S., Meuris, N., Castermans, E., Baudoux, E., Frere, P., Bours, V., Fillet, G., & Beguin, Y. (2003). T-cell reconstitution after unmanipulated, CD8-depleted or CD34-selected nonmyeloablative peripheral blood stem-cell transplantation. Transplantation, 76 (12), 1705-13. doi:10.1097/01.TP.0000093987.11389.F7 Peer Reviewed verified by ORBi |
Humblet-Baron, S., Baron, F., Chachati, A., Bury, J., Morelon, E., Kreis, H., & BEGUIN, Y. (2003). Donor lymphocyte infusion for late relapse followed by kidney transplantation for end-stage renal failure after allogeneic bone marrow transplantation for chronic myeloid leukemia. Transplantation, 76 (10), 1531-2. doi:10.1097/01.TP.0000085285.59061.D7 Peer Reviewed verified by ORBi |
Hafraoui, K., Humblet-Baron, S., Baron, F., Beguin, Y., & Fillet, G. (2003). Comment je traite ... la leucemie myeloide chronique (LMC). Revue Médicale de Liège, 58 (1), 7-12. Peer reviewed |
Humblet-Baron, S., Baron, F., Pirson, L., Beguin, Y., & Fillet, G. (28 August 2002). Traitement moléculaire du cancer: le STI571, un inhibiteur des tyrosines kinases. Revue Médicale Suisse, 60 (598), 1504-1508. Peer Reviewed verified by ORBi |